(Q34344198)

English

Pathological complete response and survival according to the level of HER-2 amplification after trastuzumab-based neoadjuvant therapy for breast cancer

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Pathological complete response and survival according to the level of HER-2 amplification after trastuzumab-based neoadjuvant therapy for breast cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Frédérique Penault-Llorca

9

object named as

F Penault-Llorca

0 references

Sylvain Ladoire

6

object named as

S Ladoire

0 references

0 references

author name string

S Guiu

1

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

M Gauthier

2

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

B Coudert

3

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

F Bonnetain

4

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

L Favier

5

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

H Tixier

7

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

B Guiu

8

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

F Ettore

10

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

P Fumoleau

11

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

L Arnould

12

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

language of work or name

0 references

publication date

1 October 2010

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

British Journal of Cancer

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

103

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

9

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

1335-1342

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: the HERA Trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2990615

6 July 2018

Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2990615

6 July 2018

Phosphorylated HER-2 tyrosine kinase and Her-2/neu gene amplification as predictive factors of response to trastuzumab in patients with HER-2 overexpressing metastatic breast cancer (MBC).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2990615

6 July 2018

Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2990615

6 July 2018

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2990615

6 July 2018

Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2990615

6 July 2018

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2990615

6 July 2018

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2990615

6 July 2018

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2990615

6 July 2018

Real-world performance of HER2 testing--National Surgical Adjuvant Breast and Bowel Project experience

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2990615

6 July 2018

When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2990615

6 July 2018

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2990615

6 July 2018

HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2990615

6 July 2018

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2990615

6 July 2018

Association of c-erbB-2 protein over-expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2990615

6 July 2018

Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605939

21 January 2018

Pre-operative systemic (neo-adjuvant) therapy with trastuzumab and docetaxel for HER2-overexpressing stage II or III breast cancer: results of a multicenter phase II trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605939

21 January 2018

Current issues in ER and HER2 testing by IHC in breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605939

21 January 2018

Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605939

21 January 2018

Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605939

21 January 2018

Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605939

21 January 2018

Long-term outcome and pattern of relapse after neoadjuvant chemotherapy in patients with human epidermal growth factor receptor 2-positive primary breast cancer.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605939

21 January 2018

2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605939

21 January 2018

Neoadjuvant trastuzumab and docetaxel in breast cancer: preliminary results

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2990615

27 October 2018

Multicenter Phase II Trial of Neoadjuvant Therapy With Trastuzumab, Docetaxel, and Carboplatin for Human Epidermal Growth Factor Receptor-2–Overexpressing Stage II or III Breast Cancer: Results of the GETN(A)-1 Trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605939

21 January 2018

Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831

1 reference

https://pubmed.ncbi.nlm.nih.gov/20978512

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetics, Safety, and Efficacy of Trastuzumab Administered Every Three Weeks in Combination With Paclitaxel

1 reference

https://pubmed.ncbi.nlm.nih.gov/20978512

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of preoperative chemotherapy on the outcome of women with operable breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/20978512

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/20978512

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab

1 reference

https://pubmed.ncbi.nlm.nih.gov/20978512

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/20978512

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pathologic complete response to trastuzumab-based neoadjuvant therapy is related to the level of HER-2 amplification

1 reference

https://pubmed.ncbi.nlm.nih.gov/20978512

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High concordance between immunohistochemistry and fluorescence in situ hybridization testing for HER2 status in breast cancer requires a normalized IHC scoring system

1 reference

https://pubmed.ncbi.nlm.nih.gov/20978512

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

New cutpoints to identify increased HER2 copy number: analysis of a large, population-based cohort with long-term follow-up

1 reference

https://pubmed.ncbi.nlm.nih.gov/20978512

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Level of HER2/neu gene amplification as a predictive factor of response to trastuzumab-based therapy in patients with HER2-positive metastatic breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/20978512

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/SJ.BJC.6605939

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34344198&oldid=2196528883"